WO2021075662A1 - Composition de biomarqueur comprenant mir-320c en tant que principe actif pour la prédiction de la réactivité à un médicament d'un patient atteint d'un cancer du sein triple négatif à un agent anticancéreux à base de platine - Google Patents

Composition de biomarqueur comprenant mir-320c en tant que principe actif pour la prédiction de la réactivité à un médicament d'un patient atteint d'un cancer du sein triple négatif à un agent anticancéreux à base de platine Download PDF

Info

Publication number
WO2021075662A1
WO2021075662A1 PCT/KR2020/007605 KR2020007605W WO2021075662A1 WO 2021075662 A1 WO2021075662 A1 WO 2021075662A1 KR 2020007605 W KR2020007605 W KR 2020007605W WO 2021075662 A1 WO2021075662 A1 WO 2021075662A1
Authority
WO
WIPO (PCT)
Prior art keywords
mir
platinum
breast cancer
triple negative
negative breast
Prior art date
Application number
PCT/KR2020/007605
Other languages
English (en)
Korean (ko)
Inventor
박종훈
임세라
김예솔
Original Assignee
지니너스 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 지니너스 주식회사 filed Critical 지니너스 주식회사
Publication of WO2021075662A1 publication Critical patent/WO2021075662A1/fr

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne une composition de biomarqueur comprenant miR-320c en tant que principe actif pour la prédiction de la réactivité à un médicament d'un patient atteint d'un cancer du sein triple négatif à un agent anticancéreux à base de platine. Les présents inventeurs ont découvert que la régulation directe de l'expression de CHEK1 par miR-320c, qui est régulée à la baisse dans la plupart des lignées cellulaires TNBC. À travers de nouvelles recherches, les présents inventeurs ont révélé que la restauration ectopique de miR-320c dans des cellules TNBC traitées par oxaliplatine supprime une réponse liée à l'endommagement d'ADN et à la réparation d'ADN, améliore l'instabilité génomique, et active l'apoptose par la régulation négative de CHEK1. En outre, une combinaison d'un mimétique de miR-320c et d'oxaliplatine inhibe efficacement la progression tumorale. Les résultats montrent que miR-320c joue un rôle important dans la réactivité des dellules TNBC à l'oxaliplatine par régulation de l'expression de CHEK1, ce qui implique que, en tant que cible thérapeutique pour augmenter la réactivité à la chimiothérapie, miR-320c est attendu pour trouver des applications avantageuses dans une stratégie thérapeutique pour le cancer du sein triple négatif.
PCT/KR2020/007605 2019-10-18 2020-06-11 Composition de biomarqueur comprenant mir-320c en tant que principe actif pour la prédiction de la réactivité à un médicament d'un patient atteint d'un cancer du sein triple négatif à un agent anticancéreux à base de platine WO2021075662A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020190130038A KR102251864B1 (ko) 2019-10-18 2019-10-18 miR-320c를 유효성분으로 포함하는 백금계 항암제에 대한 삼중음성유방암 환자의 약물 반응성 예측용 바이오마커 조성물
KR10-2019-0130038 2019-10-18

Publications (1)

Publication Number Publication Date
WO2021075662A1 true WO2021075662A1 (fr) 2021-04-22

Family

ID=75537411

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2020/007605 WO2021075662A1 (fr) 2019-10-18 2020-06-11 Composition de biomarqueur comprenant mir-320c en tant que principe actif pour la prédiction de la réactivité à un médicament d'un patient atteint d'un cancer du sein triple négatif à un agent anticancéreux à base de platine

Country Status (2)

Country Link
KR (1) KR102251864B1 (fr)
WO (1) WO2021075662A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2354246A1 (fr) * 2010-02-05 2011-08-10 febit holding GmbH ARNm dans le diagnostic du cancer ovarien
KR20140104419A (ko) * 2011-11-25 2014-08-28 인테그라겐 Egfr 억제제를 사용한 치료에 대한 반응을 예측하는 방법
WO2015171510A2 (fr) * 2014-05-05 2015-11-12 The Regents Of The University Of California Microarn (miarn) circulants utilisables en tant que biomarqueurs de la rétinopathie diabétique (rd) et de la dégénérescence maculaire liée à l'âge (dmla)
WO2019115748A1 (fr) * 2017-12-14 2019-06-20 Unicyte Ev Ag Vehicules pharmaceutiques contenant des arnmi pour leur utilisation dans le traitement du cancer du rein

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2354246A1 (fr) * 2010-02-05 2011-08-10 febit holding GmbH ARNm dans le diagnostic du cancer ovarien
KR20140104419A (ko) * 2011-11-25 2014-08-28 인테그라겐 Egfr 억제제를 사용한 치료에 대한 반응을 예측하는 방법
WO2015171510A2 (fr) * 2014-05-05 2015-11-12 The Regents Of The University Of California Microarn (miarn) circulants utilisables en tant que biomarqueurs de la rétinopathie diabétique (rd) et de la dégénérescence maculaire liée à l'âge (dmla)
WO2019115748A1 (fr) * 2017-12-14 2019-06-20 Unicyte Ev Ag Vehicules pharmaceutiques contenant des arnmi pour leur utilisation dans le traitement du cancer du rein

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MALLA RAMA RAO; KUMARI SEEMA; GAVARA MURALI MOHAN; BADANA ANIL KUMAR; GUGALAVATH SHAILENDER; KUMAR DEEPAK KAKARA; ROKKAM PRASUJA: "A perspective on the diagnostics, prognostics, and therapeutics of microRNAs of triple-negative breast cancer", BIOPHYSICAL REVIEWS, SPRINGER, DE, vol. 11, no. 2, 22 February 2019 (2019-02-22), DE, pages 227 - 234, XP036743338, ISSN: 1867-2450, DOI: 10.1007/s12551-019-00503-8 *

Also Published As

Publication number Publication date
KR102251864B1 (ko) 2021-05-14
KR20210046389A (ko) 2021-04-28

Similar Documents

Publication Publication Date Title
Zhou et al. Long noncoding RNA SNHG16 targets miR-146a-5p/CCL5 to regulate LPS-induced WI-38 cell apoptosis and inflammation in acute pneumonia
Li et al. Mex3a promotes oncogenesis through the RAP1/MAPK signaling pathway in colorectal cancer and is inhibited by hsa‐miR‐6887‐3p
Ding et al. Triptolide suppresses proliferation, hypoxia-inducible factor-1α and c-Myc expression in pancreatic cancer cells
Han et al. LncRNA-p21 inhibited the proliferation of osteosarcoma cells via the miR-130b/PTEN/AKT signaling pathway
Wu et al. MiR-18b suppresses high-glucose-induced proliferation in HRECs by targeting IGF-1/IGF1R signaling pathways
KR101198046B1 (ko) ＴＴＰ 프로모터 내 특정 단일 ＣｐＧ 부위의 후생유전학적 지표를 이용한 암 발병／예후 진단 및 이의 조절을 통한 암 치료기술
Liu et al. eIF4E promotes tumorigenesis and modulates chemosensitivity to cisplatin in esophageal squamous cell carcinoma
Liang et al. MicroRNA-873 acts as a tumor suppressor in esophageal cancer by inhibiting differentiated embryonic chondrocyte expressed gene 2
Luo et al. TGF-β1 promotes cell migration in hepatocellular carcinoma by suppressing reelin expression
Xiao et al. MiR‐340 suppresses the metastasis by targeting EphA3 in cervical cancer
US20210361694A1 (en) Method for preventing or treating cancer using syt11 inhibitor
KR20180044617A (ko) Uhrf1 및 dnmt1을 포함하는 세포 노화 진단용 바이오마커 조성물
Li et al. MiR-214 regulates oral cancer KB cell apoptosis through targeting RASSF5
Zhu et al. CPSF6-mediated XBP1 3’UTR shortening attenuates cisplatin-induced ER stress and elevates chemo-resistance in lung adenocarcinoma
Wang et al. MiR-495/IGF-1/AKT signaling as a novel axis is involved in the epithelial-to-mesenchymal transition of oral squamous cell carcinoma
Li et al. miR-183 inhibits UV-induced DNA damage repair in human trabecular meshwork cells by targeting of KIAA0101
Wu et al. MiR-628–5p Inhibits Cervical Carcinoma Proliferation and Promotes Apoptosis by Targeting VEGF
Liu et al. Long noncoding RNA RFPL1S-202 inhibits ovarian cancer progression by downregulating the IFN-β/STAT1 signaling
Wang et al. A positive feedback loop between GRP78 and VPS34 is critical for GRP78-mediated autophagy in cancer cells
Wang et al. linc00174 deteriorates the pathogenesis of diabetic retinopathy via miR-26a-5p/PTEN/Akt signalling cascade-mediated pyroptosis
KR20210042290A (ko) Tut4/7 발현 조절인자를 포함하는 암 예방 또는 치료용 약학적 조성물
WO2021075662A1 (fr) Composition de biomarqueur comprenant mir-320c en tant que principe actif pour la prédiction de la réactivité à un médicament d'un patient atteint d'un cancer du sein triple négatif à un agent anticancéreux à base de platine
US11510911B2 (en) Method for prediction of susceptibility to sorafenib treatment by using SULF2 gene, and composition for treatment of cancer comprising SULF2 inhibitor
Zhong et al. Aberrant DNA methylation of synaptophysin is involved in adrenal cortisol-producing adenoma
Song et al. Downregulation of miR‑7 and miR‑153 is involved in Helicobacter pylori CagA induced gastric carcinogenesis and progression

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20876400

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20876400

Country of ref document: EP

Kind code of ref document: A1